SPR206 acetate|cas:2408422-41-1|西域试剂

SPR206 acetate,99.74%

产品编号：Bellancom-128780B| CAS NO：2408422-41-1| 分子式：C₅₂H₈₂ClN₁₅O₁₂.xC₂H₄O₂

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	价格	库存与货期
Bellancom-128780B	￥9500.00	杭州北京（现货）
Bellancom-128780B	￥15000.00	杭州北京（现货）
Bellancom-128780B	￥42000.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

SPR206 acetate

产品介绍

SPR206 acetate 是一种多粘菌素类似物，对包括多重耐药的革兰氏阴性病原体具有抗生素活性。SPR206 acetate 通过与细菌的外膜相互作用而具有抗菌感染作用。SPR206 acetate 对铜绿假单胞菌 Pa14 菌株和鲍曼不动杆菌 NCTC13301 菌株的 MIC 值均为 0.125 mg/L。

生物活性

SPR206 acetate is a polymyxin analog with antibiotic activity against Gram-negative pathogens, including multidrug-resistant (MDR) variants. SPR206 acetate has an anti-bacterial infection effect by interacting with the bacterium’s outer membrane. The MIC values of SPR206 acetate against Pseudomonas aeruginosa Pa14 and Acinetobacter baumannii NCTC13301 are both 0.125 mg/L.

体外研究

SPR206 exhibits strong anti-microbial properties against Gram-negative bacteria. The MIC values of SPR206 against E. coli IHMA558090, E. coli ATCC 25922, K. pneumonia ATCC 13882, P. aeruginosa ATCC 27853, A. baumannii NCTC13424 and A. baumannii ATCC 19003 are 8 mg/L, 0.125 mg/L, 0.125 mg/L, 0.25 mg/L, 0.06 mg/L and 0.125 mg/L, respectively, together with lower cytotoxicity .

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究

SPR206 (0.125-30 mg/kg; intravenous injection or subcutaneous injection; every 8 hours or every 4 hours; for 16 hours or 24 hours; neutropenic mice) treatment reduces the burden of Pa14 and NCTC13301 in lung tissue and in the thigh model.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Neutropenic mice infected Pa14 or NCTC13301
Dosage:	3 mg/kg, 10 mg/kg, 20 mg/kg, 30 mg/kg (intravenous injection); 0.125 mg/kg, 0.5 mg/kg, 1 mg/kg, 4 mg/kg (subcutaneous injection)
Administration:	Intravenous injection or subcutaneous injection; every 8 hours or every 4 hours; for 16 hours or 24 hours
Result:	In lung tissue, reduced the burden of Pa14 and NCTC13301 by 1.5 and 3.6 log₁₀ CFU/mL. In the thigh model, reduced the burden of Ab13301 by 3.4 and 4.3 log₁₀ CFU/g.

体内研究

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Neutropenic mice infected Pa14 or NCTC13301
Dosage:	3 mg/kg, 10 mg/kg, 20 mg/kg, 30 mg/kg (intravenous injection); 0.125 mg/kg, 0.5 mg/kg, 1 mg/kg, 4 mg/kg (subcutaneous injection)
Administration:	Intravenous injection or subcutaneous injection; every 8 hours or every 4 hours; for 16 hours or 24 hours
Result:	In lung tissue, reduced the burden of Pa14 and NCTC13301 by 1.5 and 3.6 log₁₀ CFU/mL. In the thigh model, reduced the burden of Ab13301 by 3.4 and 4.3 log₁₀ CFU/g.

性状

Solid

溶解性数据

In Vitro:

DMSO : ≥ 100 mg/mL

* "≥" means soluble, but saturation unknown.

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

1.

请依序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% saline
Solubility: ≥ 2.5 mg/mL (Infinity mM); Clear solution

此方案可获得 ≥ 2.5 mg/mL (Infinity mM，饱和度未知) 的澄清溶液。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。
将 0.9 g 氯化钠，完全溶解于 100 mL ddH₂O 中，得到澄清透明的生理盐水溶液
2.

请依序添加每种溶剂： 10% DMSO 90% (20% SBE-β-CD in saline)
Solubility: ≥ 2.5 mg/mL (Infinity mM); Clear solution

此方案可获得 ≥ 2.5 mg/mL (Infinity mM，饱和度未知) 的澄清溶液。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。
将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中，再用生理盐水定容至 10 mL，完全溶解，澄清透明
3.

请依序添加每种溶剂： 10% DMSO 90% corn oil
Solubility: ≥ 2.5 mg/mL (Infinity mM); Clear solution

此方案可获得 ≥ 2.5 mg/mL (Infinity mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。